TABLE 5.
Multivariable models for factors associated with receiving treatment
| Variable | Antenatal corticosteroid for fetal lung maturity (n = 500 eligible),a RR (CI) | Progesterone for prevention of preterm birth (n = 753 eligible),b RR (CI) | Magnesium sulfate for neuroprotection (n = 181 eligible),c RR (CI) |
|---|---|---|---|
| Insurance status | |||
| Uninsured or self-pay | 0.27 (0.14–0.51) | 1.34 (1.03–1.75) | |
| Government assisted | 0.72 (0.52–1.01) | 1.20 (0.97–1.49) | |
| Private | 1.00 (referent) | 1.00 (referent) | |
| Preterm premature rupture of the membranes | 0.93 (0.88–0.99) | ||
| Attending years since graduated medical school | |||
| 0–9.9 (includes no attending at delivery) | 1.00 (referent) | ||
| 10–14.9 | 1.02 (0.97–1.08) | ||
| 15–19.9 | 1.01 (0.95–1.07) | ||
| 20–24.9 | 0.84 (0.72–0.98) | ||
| ≥25 | 0.99 (0.92–1.05) | ||
| Provider rated the quality of the evidence for the intervention as above average to excellent | 2.38 (1.56–3.63) | ||
| Difficulty with hospital or pharmacy drug delivery | 0.57 (0.40–0.83) |
CI, confidence interval; RR, relative risk.
Patients eligible for antenatal corticosteroid for fetal lung maturity were those who delivered in the labor and delivery department before 34 weeks of gestation and delivered 4 or more hours after admission;
Patients eligible for progesterone for the prevention of preterm birth were those who delivered in the labor and delivery department with a singleton pregnancy, with a history of a prior spontaneous preterm delivery, who had at least 2 prenatal care visits, and whose pregnancy was dated by a first or second trimester ultrasound or had assisted reproductive technology;
Patients eligible for magnesium sulfate for neuroprotection were those who delivered in the labor and delivery department before 32 weeks of gestation, did not have gestational hypertension or pre-eclampsia, and delivered 4 or more hours after admission.